RUNX1 and cancer: To identify the role of RUNX1 in TGFβ1-driven motility and EMT in colorectal cancer cells, we treated HT29 and LS174 colorectal cancer cells with TGFβ1 in the presence or absence of Ro5-3335 for 24 h followed by immunoblotting using anti-ARP2/3 and anti-vimentin antibodies representing cancer cell invasion71 and EMT72, respectively.